LA JOLLA

hier

Datum Erster Hoch Tief Schluss     Stücke Volumen
26.03.13 0,094 0,094 0,09  0,091 $ 35.199 3.194

board Anzeige: 0,09 ..aber an der Ami-Tafel stehen als SK 0,091 und der EK war 0,094 somit 0,003 USD unterschlagen SKANDAL ..buran (macht nüscht die paar Fusseln) ;o)  

letzter Satz vom 02-04-13

nur wollte keiner den spread von 37,78% opfern ..verständlich ..trotzdem gutes Angebot von 0,124 $ und 1.000 waren und sind drin ..wir arbeiten daran

....................Pott dicke +50,79% buran und MfG  

Marktkap. 1,29 Mio. $ : Aktienanzahl 13,6 Mio.
GrB  

0,0679 $ +4,46% +0,0029 $ , 05.08.13 , Pott +7,78% , GrB  

und die Nasdaq sich regt ..dann ist auch was Schöne dabei das Du Dir kannst wünschen ..alle Deine Wünsche werden in Erfüllung gehen ..Du musst nur an Sterne und Nasdaq drehen

Zeit  Kurs  Stück  
15:38:10 0,0679 $  3.000  
15:30:11 0,0679 $  4.000
____________________
GRATULATION ..zwei KOs bedient somit ausgeführt ..buran und danke und weitermachen
 

Datum Erster Hoch Tief Schluss     Stücke Volumen
20.08.13 0,068 0,068 0,06  0,0601 $ 71.544 4.450

GrB  

Zeit  Kurs  Stück  
15:30:15 0,0809 $  2.533  
15:30:15 0,08 $  3.000  
15:30:00 0,08 $  2.000

..ulla ..ulla ..oleeee ..watt iss doch LA JOLLA am Börsen Ticker schei
 

is a biopharmaceutical company dedicated to the development of treatments that significantly improve outcomes in patients with life-threatening diseases. Our team is pioneering the science of galectins to develop innovative new therapies to treat human diseases such as cancer and chronic organ failure.

schöne 11er Ticker Schluss Lampe:::::

::::0,078 $ +13,87% +0,0095 $ In Euro: 0,0587 € | Nasdaq OTC BB, 11.09.13

buran und MfG olee olee  

Datum Erster Hoch Tief Schluss     Stücke Volumen
25.09.13 0,0851 0,086 0,0722  0,08 $ 634.102 50 T

GrB  

is dedicated to the development of treatments that significantly improve outcomes in patients with life-threatening diseases.  Our current efforts focus on the clinical evaluation of GCS-100, a galectin antagonist, as a treatment for chronic organ disease and LJPC-501, an antagonist of the renin-angiotensin pathway, as a treatment for hepatorenal syndrome, a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure.  In addition, our experienced team of scientists are expanding our pipeline by developing innovative new therapies to treat diseases of the liver and lung as well as cancer.

http://ljpc.com/  

http://ljpc.com/corporate/xbrl-filings/ GrB  

http://ljpc.com/corporate/sec-fillings/ GrB  

SEC Accession No. 0001193125-13-377211

2013-09-25
Accepted2013-09-25 08:32:02
Documents8Period of Report2013-09-24
Filing Date Changed2013-09-25ItemsItem 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits
http://www.sec.gov/Archives/edgar/data/920465/...-13-377211-index.htm  

La Jolla Pharmaceutical Company to Present at the Rodman & Renshaw Annual Global Investment Conference on September 9, 2013
SAN DIEGO, CA–(Marketwired – Sep 5, 2013) - La Jolla Pharmaceutical Company (OTCBB: LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that the Company will present at the Rodman & Renshaw Global Investment Conference. George F. Tidmarsh, MD, PhD, President and Chief Executive Officer of La Jolla will present at 4:30 pm Eastern Time on Monday, September 9th. The conference will be held in the Millennium Broadway Hotel in New York City.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501 is a product candidate for the treatment of hepatorenal syndrome. For more information on the Company please visit http://www.ljpc.com.

Forward Looking Statement Safe Harbor

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), all of which are available free of charge on the SEC's web site http://www.sec.gov. These risks include, but are not limited to, risks relating to the development of GCS-100 and LJPC-501, the success and timing of future preclinical and clinical studies of these compounds, and potential indications for which GCS-100 and LJPC-501 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.



Company Contact



George F. Tidmarsh, M.D., Ph.D.

President & Chief Executive Officer
La Jolla Pharmaceutical Company

Phone: (858) 207-4264

Email: GTidmarsh@ljpc.com



and



Chester S. Zygmont, III

Director of Finance
La Jolla Pharmaceutical Company

Phone: (858) 207-4262

Email: czygmont@ljpc.com
http://ljpc.com/...-global-investment-conference-on-september-9-2013/  

Zeit  Kurs  Stück  
15:30:13 0,08 $  3.000  
15:30:04 0,08 $  7.000
__________________
GRATULATION ..zwei schöne KOs  

RTK 0,08 $ RTP +0,00 Pott +26,98% ,GrB
   

Datum Erster Hoch Tief Schluss     Stücke Volumen
14.10.13 0,182 0,185 0,175  0,18 $ 298.171 54 T

GrB  

Zeit
                Kurs               Stück                    §
  21:58:44§0,184 $
               7.500                    §
  21:58:23§0,183 $
               2.500                    §
  21:51:01§0,184 $
               5.200                    §
  21:43:31§0,184 $
               2.500                    §
  21:42:22§0,183 $
               2.500                    §
  21:38:47§0,179 $
               5.000                    §
  21:31:01§0,179 $
               2.999                    §
  21:30:26§0,17 $
              16.000                    §
  21:30:00§0,17 $
              15.000                    §
  21:29:47§0,17 $
              10.000                    §
  21:28:57§0,1695 $
              10.000                    §
  21:28:30§0,1695 $
               5.000                    §
  21:23:27§0,1695 $
              10.000                    §
  21:18:07§0,1641 $
               6.000                    §
  21:05:43§0,1641 $
               2.000                    §
  21:04:41§0,1641 $
               5.000                    §
  21:03:23§0,1695 $
              10.000                    §
  21:00:18§0,1695 $
          10.000
§
buran  

LA JOLLA SK 0,184  $ SKP +12,20% EK 0,164 $ last shares 7.500 full 127.199 max Leuchte 0,184

Kosmonova buran  

Zeit
                Kurs               Stück                    §
  18:14:42§0,1811 $
              75.480                    §
  18:14:28§0,189 $
                 480                    §
  18:14:28§0,185 $
              25.000                    §
  18:08:16§0,1898 $
                 100                    §
  17:35:53§0,1811 $
               4.000                    §
  17:35:48§0,1811 $
               4.000                    §
  17:30:46§0,1898 $
               4.000                    §
  16:56:16§0,1811 $
                 360                    §
  16:56:07§0,1811 $
               4.640                    §
  16:48:40§0,1898 $
               5.000                    §
  16:48:36§0,1898 $
                 450                    §
  16:18:07§0,182 $
               1.359                    §
  15:50:52§0,182 $
                 300                    §
  15:42:08§0,182 $
              12.000                    §
  15:41:10§0,1835 $
               2.000                    §
  15:34:56§0,1898 $
                 200                    §
  15:32:36§0,1898 $
              15.500                    §
  15:32:06§0,1898 $
              10.000§
GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
20.11.13 0,1699 0,174 0,12   0,1275 $ 2.513.933 347 T

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  27.11.13     0,148     0,148§0,135 0,145 $ 271.196 34.817

GrB  

::::::::::: 0,157 $ +1,95% +0,003 $
In Euro: 0,1154 € | Nasdaq OTC BB, 07.01.14::::: sagt der Igel zu dem Stachelschwein  

::::::::::::: 0,158 $ +4,64% +0,007 $
In Euro: 0,1159 € | Nasdaq OTC BB, 13.01.14::::: doch soviele schöne Sachen machen ..allein oder in einer Gruppe ..mach doch einfach mit hier ..das wird lustig und mal zur Abwechslung was anderes tolles

buran,Die Börsen LA JOLLA Erlebnis Pädagogin
 

Zeit    Kurs Stück
  15:33:04§ 10,6501 $ 500
  15:33:03§ 10,65 $ 100
  15:32:25§ 10,67 $ 100
  15:30:00§ 10,97 $ 1.690
____________________
GRATULATION